Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
作者： Mathew Gelfand
DOI:
关键词:
摘要: The present invention relates to a method and device for treating patients with Protein Misfolding Disease by chronically administering an effective dose of thormbolytic reagent over intermittent period time. thrombolytic reagents degrade the misfolded proteins that accumulate can become toxic in such patients. administration is administered transdermally via transdermal patch equipped ultrasound transducer enhancing penetration into bloodstream patient increasing permeability patient's skin.
lens.org 参考文章(8)
Robert Martin Gale, Methods for transdermal drug administration ,(1999)
Kurt R. Brunden, Carlo Ballatore, Alex Crowe, Amos B. Smith,, Virginia M.-Y. Lee, John Q. Trojanowski, Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Experimental Neurology. ,vol. 223, pp. 304- 310 ,(2010) , 10.1016/J.EXPNEUROL.2009.08.031
Stuart Mcrae, David Enscore, Frank Tagliaferri, Gaurav Tolia, Shulun Chang, Yogi Patel, Alan Smith, Jonathan Eppstein, Permeant delivery system and methods for use thereof ,(2006)
George J Despotis, J Heinrich Joist, Lawrence T Goodnough, Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes Clinical Chemistry. ,vol. 43, pp. 1684- 1696 ,(1997) , 10.1093/CLINCHEM/43.9.1684
Henry Schur, Joseph P. D'Angelo, Method of transdermally administering high molecular weight drugs with a polymer skin enhancer ,(1996)
Bruce Alan Keyt, Nicholas F. Paoni, William F. Bennett, Tissue plasminogen activator glycosylation variants with improved therapeutic properties ,(1993)
Barend Bouma, Onno Wouter Kranenburg, Martijn Frans Ben Gerard Gebbink, Louise Maria Johanna Kroon, Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity ,(2003)
Mathew I. Gelfand, Use of thrombolytic reagents for prevention of vascular disease ,(1996)